2019 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | > 1000 |
Total number of projects: 3
As coordinator: 0
As participant: 3
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2022 | 0 | 238.994 | 0 | 1 | ||
2021 | 0 | 92.500.000 | 869.670 | 1 | ||
2019 | 0 | 910.800 | 0 | 1 |
Total number of partners: 41
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 41
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2022-05-01 | Mycobacteriophages to treat tuberculosis - Passed station or future promise? | Phage-TB | participant | 238.994 | 3 |
2021-06-01 | ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS | UNITE4TB | participant | 92.500.000 | 32 |
2019-04-01 | European-Latin American TB Research Collaboration Network | EUSAT-RCS | participant | 910.800 | 9 |